Pomegra
Regeneron Stock Jumps 13% After Record Q3 Earnings
Why did Regeneron stock jump 13%?
Regeneron (REGN) stock rose 13.3% to $927.89 on Friday after record third-quarter earnings and an expanded Sanofi alliance worth up to $8B, as sales jumped 36%.
Key numbers
| Q3 revenue | $5.12B+36% YoY |
|---|---|
| Adjusted EPS | $20.07+70% YoY |
| Sanofi collaboration revenue | $2.72B+68% YoY (per [4]) |
| Dupixent global sales | $6.5B+35% YoY |
| REGN close, Oct 30 | $927.89+13.3% (intraday reports showed 11–12%) |
What happened
Regeneron (REGN) stock rose 13.3% to $927.89 on Friday after record third-quarter earnings and an expanded Sanofi alliance worth up to $8B, as sales jumped 36%. Sales reached $5.1 billion, and adjusted profit per share jumped 70% to $20.07, beating forecasts of about $16. Regeneron also began collecting its full share of profits from Dupixent, a drug it sells with Sanofi, lifting Sanofi-related revenue 68% to $2.7 billion. Sanofi will pay $1 billion upfront and up to $7 billion more in milestones.
Why it matters
Regeneron's 13% jump shows how much one successful drug partnership can lift a company's profits. Dupixent sales grew 35% to $6.5 billion in the quarter, and Regeneron now keeps its full profit share. The expanded Sanofi deal adds new long-acting antibody drugs, so the partnership can reach beyond Dupixent. Regeneron also nudged up its 2026 profit-margin outlook (guidance).
Who this affects
- MarketbullishMedium impact
- Biotech investors see strong earnings; Regeneron shareholders gain sharply.
- CompanybullishHigh impact
- Regeneron gains record sales, full Dupixent profits and $1B upfront cash.
- CompetitorsneutralLow impact
- Rival immunology drugmakers face a stronger Regeneron-Sanofi pairing.
- IndustrybullishMedium impact
- Big drug partnerships look more valuable; deal terms may guide others.
Regeneron vs Moderna, Merck, Pfizer
How we got here
Regeneron reports Q2 revenue of $4.29B, up 17% from a year earlier.
Regeneron reports record Q3 results and expands Sanofi alliance; shares close up 13.3%.
Coverage notes shares near the $935.35 52-week high, with a market value near $96B.
What to watch
- Fourth-quarter report, when Regeneron books the $1B Sanofi upfront payment.Q4 2026
- Whether Regeneron adds Sanofi's lunsekimig, a COPD drug now in Phase 3 testing.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
CVS Stock Rises 1.2% After Hours on Pharmacy Spin-Off Report
CVS Health (CVS) would spin off 9,000 drugstores by 2028, undoing its $78B Aetna deal amid political pressure.
Oil Falls 1.1% on Iran Peace Talk Hopes
Brent crude (BZ=F) fell for a second day, the S&P 500 rose 0.4%, and Trump said US aid to Israel will end.
Palantir Stock Falls 1.7% on Q3 Earnings as Contract Growth Slows
Palantir (PLTR) beat revenue estimates with sales up 96%, but slower new-contract growth worried investors.